Non-Inferiority Trials in Medicine: Practice Changing or a Self-Fulfilling Prophecy?

Vinay Prasad^{1

2

3}

Affiliations

¹ Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA. prasad@ohsu.edu.
² Department of Preventive Medicine and Public Health, Oregon Health and Science University, Portland, OR, USA. prasad@ohsu.edu.
³ Center for Health Care Ethics, Oregon Health and Science University, Portland, OR, USA. prasad@ohsu.edu.

Editorial

Vinay Prasad. J Gen Intern Med. 2018 Jan.

. 2018 Jan;33(1):3-5.

doi: 10.1007/s11606-017-4191-y.

Vinay Prasad^{1

2

3}

¹ Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA. prasad@ohsu.edu.
² Department of Preventive Medicine and Public Health, Oregon Health and Science University, Portland, OR, USA. prasad@ohsu.edu.
³ Center for Health Care Ethics, Oregon Health and Science University, Portland, OR, USA. prasad@ohsu.edu.

No abstract available

Conflict of interest statement

Dr. Prasad receives royalties from his book Ending Medical Reversal.

Empirical Consequences of Current Recommendations for the Design and Interpretation of Noninferiority Trials.
Aberegg SK, Hersh AM, Samore MH. Aberegg SK, et al. J Gen Intern Med. 2018 Jan;33(1):88-96. doi: 10.1007/s11606-017-4161-4. Epub 2017 Sep 5. J Gen Intern Med. 2018. PMID: 28875400 Free PMC article. Review.

1. Aberegg Scott K., Hersh Andrew M., Samore Matthew H. Empirical Consequences of Current Recommendations for the Design and Interpretation of Noninferiority Trials. Journal of General Internal Medicine. 2017;33(1):88–96. doi: 10.1007/s11606-017-4161-4. - DOI - PMC - PubMed
1. Djulbegovic B, Kumar A, Glasziou P, et al. Medical research: trial unpredictability yields predictable therapy gains. Nature. 2013;500(7463):395–96. doi: 10.1038/500395a. - DOI - PMC - PubMed
1. Suda KJ, Hurley AM, McKibbin T, et al. Publication of noninferiority clinical trials: changes over a 20-year interval. Pharmacotherapy. 2011;31(9):833–9. doi: 10.1592/phco.31.9.833. - DOI - PubMed
1. Flacco ME, Manzoli L, Boccia S, et al. Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. J Clin Epidemiol. 2015;68(7):811–20. doi: 10.1016/j.jclinepi.2014.12.016. - DOI - PubMed
1. Piaggio G, Elbourne DR, Pocock SJ, et al. Reporting of noninferiority and equivalence randomized trials: extension of the consort 2010 statement. JAMA. 2012;308(24):2594–604. doi: 10.1001/jama.2012.87802. - DOI - PubMed